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These are the 'best of times, the worst of times' for cancer
chemotherapy. The bad news is that we have reached a
plateau of efficacy in the most responsive cancers and our
current agents have only restricted impact upon the major
common solid tumours. The good news is that this realisa-
tion has led to a refreshing dissatisfaction with conventional
drugs and the screening systems which identified them.
Coupled to this is a healthy spirit of optimism, at least in
some quarters, for the discovery of totally new chemical
entities expressing entirely novel mechanisms of therapeutic
action against human cancer cells.
The revolutionary context of the opening quote from A
Tale of Two Cities is therefore most appropriate, particularly
as 1989 was the bicentenary of the French Revolution. But
the previous year, 1988, will be remembered even better by
pharmacologists for the timely award of the Nobel prize
in Physiology and Medicine to George Hitchings, Gertrude
Elion and Sir James Black, in recognition of their outstand-
ing contributions to innovative drug discovery. The work of
Hitchings and Eliot resulted in the development of numerous
valuable antimetabolites, while Black's led to the ,3-blockers
and histamine-H2 antagonists. Their success illustrates most
vividly the value of a strategy known widely as 'enlightened
empiricism'. Extraordinary therapeutic selectivity can be pro-
duced by blockade of specific enzymes or receptors.
Serendipity and intuition will always play a significant role
in drug discovery - that is after all part of the fun - but a
rational, mechanism-based approach is now seen by many as
the real key to true therapeutic innovation. Recent years
have witnessed major improvements in the tools of the trade
for rational drug development. Highly sophisticated techniques
are now readily available, and molecular engineering is a
reality. In Europe especially, fast-track procedures are in
place to guarantee rapid but rigorous toxicological and early
clinical evaluation of novel anti-cancer agents. Even more
important, perhaps, are the breakthroughs in recombinant
DNA and monoclonal antibody technologies. Oncogenes,
growth factors and cell signalling pathways have emerged as
exciting new targets for drug design.
This is the climate of opinion which has generated the
second volume of CRC Press's Developments in Cancer
Chemotherapy. Comparison with the first indicates how the
subject has moved over the past five years. In his brief
preface, the editor indicates his intention to cover a variety of
approaches in which molecular biological advances provide
us with new insights into experimental therapeutics. How
well has this goal been achieved?
Opening, Glazer et al. cover differentiation of leukaemic
cells with inevitable emphasis on the HL-60 model. It is
encouraging to see what is often a phenomenological topic
given a biochemical perspective, and this sets the flavour of
the book. The potential roles of protein kinase C, calcium
and inositol lipid signalling, and cellular oncogenes are intro-
duced. Possible leads to new therapy discussed here include
tyrosine kinase inhibitors; inhibition of oncogene expression
or oncoprotein function; modulation ofprotein kinase C and
G-proteins; and agonists of GM-CSF.
Following this, Moyer focuses more sharply on inhibition
of growth factor action. He argues that potential problems
with immunogencity and tissue penetration favour the use of
low molecular weight antagonists, such as peptide analogues
of bombesin (GRP), EGF and TGF-a. GRP antagonism is
cited as a key example. I would like to have seen a more
critical review of the problems encountered by some groups
in this area. The major advantage of inhibiting transmemb-
rane signalling as against receptor blockade is described,
namely that effects should be maintained even where growth
factor autonomy results from modified or truncated receptors
(erb B, neu and Jms); the downside is the difficulty of ensur-
ing specificity when interrupting signal transduction pathways
shared by a wide variety of hormones and growth factors
with vital physiological roles. Inhibitors of tyrosine-specific
protein kinases are discussed, including antibiotics orobol,
erbstatin and herbimycin. Like quercetin, these inhibit many
enzymes. But selectively within protein kinase subtypes can
be achieved, raising hopes for the design ofagents specific for
transforming protein kinases. Recent observations that
genistein inhibits tyrosine kinases but not cAMP-dependent
serine and threonine kinases supports this optimism. Impor-
tant sites for pharmacological intervention not discussed here
are receptor dimerisation and phosphorylation. The author
comments that, although peptide inhibitors are emerging,
difficulties with intracellular access may favour the design of
synthetic permeable drugs. Disappointingly, there is only a
brief section on modulators of phosphoinositol (P1) second
messenger signalling. This concentrates on myo-inositol
analogues as inhibitors of P1 synthetase, but omits the app-
roach of pharmacophore modelling of ligands for the protein
kinase C family based on phorbol esters, diacyl glycerol,
staurosporines and telecoidins as lead molecules. Overall, a
positive but sensibly critical review with refreshing due regard
for the basic pharmacological tenet of therapeutic selectivity.
Next at the batting crease is Tritton who plays an innings
of characteristic panache. His aim is to provide a molecular
basis for the old phenomenon of unbalanced growth. (Ques-
tion: How do cytotoxic drugs kill cells? Answer: Unbalanced
growth. End of discussion.) He approaches a solution by
trying to draw together the pleiotropic effects of doxorubicin.
Although these are unified in a speculative hypothesis, the
sheer variety of biochemical modifications induced by dox-
orubicin is itself an Achilles' heel to the argument. The
perennial problem of what is cause and what is consequence
remains. Nevertheless, this chapter provides ample food for
thought for the discriminating gourmet.
Kahn then reviews the biochemistry of the quanine
nucleotide binding G-proteins, the a-subunit of which binds
and hydrolyses GTP. The author points out that this key
function is shared with the simpler, monomeric transforming
ras-encoded p21 oncoprotein, although, in fact, more recent
data show p21 to require interaction with the GTPase
activating protein GAP to accelerate hydrolysis. In view of
the 'switched-on' state of transforming p21, Kahn advises
wrecking effector proteins rather than the GTP cycle. G-
proteins regulate phospholipase C (leading to PI turnover),
cGMP phosphodiesterase and ion channels, but evidence
from yeast supports involvement of adenylate cyclase in
transformation by ras. Very recent data not included show
human pituitary tumours to have mutations in G. which
inhibit its GTPase activity, stabilise the active GTP-bound
form, and transform by constitutive activation of adenylate
cyclase. Development of new ligands for p21 in particular
will be facilitated by the recent detailed crystal structure. I
would have liked more pharmacological speculation in this
fairly didactic chapter.
Levels of the second messenger cAMP may increase or
decrease in transformation. Cho-Chung describes novel
cAMP analogues which show remarkable selectivity for
either site I or site 2 cAMP binding sites in either type I or
type II protein kinases. New data not shown here show that
C-8 thio or halogen substituted analogues bind to the RIIp
subunit leading to modified gene transcription, probably via
the CRE sequence. Growth inhibition is seen in a wide range
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of human cell lines and xenografts, together with reverse
transformation, suppression of myc and ras proteins, and
promotion of differentiation. These exciting analogues differ
from older ones like dibutyryl cAMP, and the 8-chloro com-
pound looks promising for clinical trial.
Felsted et al. discuss another means of sabotaging transfor-
ming proteins. Certain key proteins require acylation for
location within the inner leaflet of the cell membrane. These
include not only the viral gag-encoded proteins (including
HIV) but also src and ras gene products, cAMP-dependent
protein kinases, the transferrin receptor, cytoskeletal proteins
ankyrin and vinculin, and the erythrocyte spectrin-actin
cross-linking protein band 4.1. Mutations in src and ras
which reduce acylation also inhibit transformation. The
authors describe several possible wrecking sites and favour
blockade of myristoyl/palmitoyl CoA synthesis and myristoyl/
palmitoyl transferases. It is too early to judge how selective
this will be, but it is certainly an interesting approach.
In a fairly thorough review of drug resistance, Vickers et
al. emphasise the importance of understanding the
biochemical and genetic mechanisms to permit rational cir-
cumvention manoeuvres. Particularly timely is the discussion
of glutathione-related functions and the ATP-driven P-
glycoprotein drug efflux pump in multidrug resistance
(MDR). Attention is drawn to the intriguing similarities
between MDR and chemical carcinogenesis. Emphasis here is
on resistance mechanisms rather than solutions. For example,
in the long section of P-glycoprotein, no mention is made of
anthracycline analogues (e.g. 9-alkyl, morpholino) which can
outwit the efflux pump, although some are now entering
clinical trial.
The chapter on RNA as a target for anti-metabolites by
Armstrong illustrates how modern techniques provide new
information on old drugs. For example, the differential
effects on cytoplasmic myc versus fos message are described.
Concluding, Pommier and Kohn describe the elegant elucida-
tion of interactions between intercalators or podophyllotox-
ins and topoisomerase II. Unfortunately, neither of the final
two chapters gives an idea of where their respective areas are
moving next.
The scope of this book is wide, but not totally comprehen-
sive. There is nothing here on sequence-selective DNA
targeting, for example, and very little on ether lipids. This is
a rapidly advancing field and the book is dating equally fast.
One could quibble that the authors represent solely
laboratories in the USA. Nevertheless, it will be valuable
reading to those interested in new approaches to cancer
chemotherapy. Presentational style is variable (e.g. emphasis
on personal experimental data versus overview), but this is
typical of multi-author monographs. The price will make the
book a library purchase rather than an individual one. The
publication quality is good, and I could find few typo-
graphical errors.
There are, happily, many philosophies of modern cancer
chemotherapy. Most are valid. Some are more interesting
than others. The main one to avoid is the ostrich philosophy.
Rational design, exploitation of new biochemistry and tech-
nology, and sensible screening are paramount, with
therapeutic selectivity always in mind. It needs good biology,
chemistry and interdisciplinary collaboration, and this in turn
must be energized by adequate funding. Maybe the last word
should again be from A Tale of Two Cities: 'Although it's a
long time on the road, it is on the road and coming. I tell
thee it never retreats and never stops.' Let's hope it's notfin
de siecle but a new millenium for cancer chemotherapy.
Paul Workman